Danaher acquires Precision NanoSystems

By The Science Advisory Board staff writers

June 2, 2021 -- Danaher has acquired Precision NanoSystems, a Canadian developer of genetic medicines including messenger RNA (mRNA) vaccines.

Precision NanoSystems provides technology that supports the development and manufacturing of lipid nanoparticles to help deliver genetic medicines, including mRNA vaccines. The companies cited the rapid growth of the mRNA segment as one of the reasons behind the deal.

Precision NanoSystems will join Danaher's life sciences platform and will complement other Danaher subsidiaries including Cytiva and Pall. Precision NanoSystems will continue to develop a new manufacturing center in Vancouver as planned.

Copyright © 2021 scienceboard.net

Create an Account

Already have an account? Sign in Here

To access all ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Email Preferences

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.